已收盘 03-02 16:00:00 美东时间
0.000
0.00%
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.
2025-08-17 00:21
FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target raised to $58. Concerns over age restrictions addressed with proposed new formulation."
2024-03-15 03:40
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) and Albireo Pharma (NASDAQ:ALBO...
2023-03-24 14:03
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) and Albireo Pharma (NASDAQ:ALBO...
2023-03-24 14:02
Shares of Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) have earned a consens...
2023-03-09 18:54
Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) has been assigned a consensus r...
2023-03-05 14:23
Albireo Pharma (NASDAQ:ALBO – Get Rating) is scheduled to be announcing its ear...
2023-02-26 21:22
不断增加的生物制药公司之间对资本的争夺、以及临床试验的成败导致去年生物科技行业的上市公司数量减少,一些公司被规模更大的竞争对手收购,另一些公司则倒闭收场。
2023-02-15 02:42
Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) CEO Ronald Harold Wilfred Coope...
2023-01-24 07:52
Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) was the target of a significant...
2023-01-23 22:52